Transplanting the sensitized patient

Current Opinion in Organ Transplantation

Volumn 12, Issue 4, 2007, Pages 415-419

  Crew, R John ^a   Ratner, Lloyd E ^a,b  

^a Columbia University ^*  (United States)

^b PH14 408 ^*  (United States)

Author keywords

Antibody mediated rejection; Desensitization; Donor specific antibody; Intravenous immune globulin; Plasmapheresis; Renal transplantation

Indexed keywords

IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ANTIBODY SPECIFICITY; DESENSITIZATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; FOLLOW UP; GRAFT RECIPIENT; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY SURGERY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PLASMAPHERESIS; REVIEW; RISK ASSESSMENT; SENSITIZATION; SINGLE DRUG DOSE;

EID: 34447507712     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282630878     Document Type: Review

References (29)

1. Patel R, Mickey MR, Terasaki PI. Serotyping for homotransplantations. XVI. Analysis of kidney transplants from unrelated donors. N Engl J Med 1968;279:501-506.
2. Terasaki PI, Mickey MR, Singal DP, et al. Serotyping for homotransplantations. XX. Selection of recipients for cadaver donor transplants. N Engl J Med 1968;279:1101-1103.
3. Sautner T, Gnant M, Banhegyi C, et al. Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. Transpl Int 1992; 5 (Suppl 1):S116-S120.
4. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779-787.
5. Zachary AA, Steinberg AG, Bias WB, Leffell MS. The frequencies of HLA alleles and haplotypes and their distribution among donors and renal patients in the UNOS registry. Transplantation 1996; 62:272-283.
6. HHS/HRSA/HSB/DOT; UNOS. 2006 OPTN/SRTR annual report 1996-2005. Ann Arbor: Arbor Research Collaborative for Health; 2006.
7. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58:1311-1317.
8. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66:1460-1464.
9. Lobo PI, Spencer CE, Stevenson WC, Pruett TL. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995; 59:357-360.
10. Bohmig GA, Regele H, Exner M, et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12:2482-2489.
11. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71:652-658.
12. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70:887-895.
13. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66:800-805.
14. Shah A, Nadasdy T, Arend L, et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004; 77:1399-1405.
15. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4:996-1001.
16. Bohmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7:117-121. This describes the only randomized trial to date comparing antibody reduction strategies with medication therapy alone for C4d postive antibody-mediated rejection.
17. Sun Q, Liu ZH, Ji S, et al. Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. Kidney Int 2006;70:377-383.
18. Zhatz EJ, Crew RJ, Schwartz J, et al. Renal allograft antibody-mediated rejection: Treatment in the present era [abstract]. Am J Transplant 2006;8:633-634.
19. Cho YW, Cecka JM. Crossmatch tests-an analysis of UNOS data from 1991-2000. Clin Transpl 2001; 237-246.
20. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57:553-562.
21. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631-636.
22. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256-3262.
23. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77:542-548.
24. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6:346-351. This study highlighted the limitations of using IVIg as a desensitization tool and suggests that more than one strategy may ultimately be necessary to get sensitized patients transplanted.
25. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7:576-585. This pathologic study suggested that a subset of patients who undergo living donor transplantation across a positive crossmatch will develop a form of subacute antibody mediated rejection that could jeopardize future allograft function.
26. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3:1017-1023.
27. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70:1531-1536.
28. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76:1519-1525.
29. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, et al. A highly efficient living donor kidney exchange program for both blood type and crossmatch incompatible donor-recipient combinations. Transplantation 2006; 82: 1616-1620. Despite requiring large numbers of donor:recipient pairs, this study shows that sensitized patients can undergo transplantation through paired:kidney exchange programs.